Meta-analysis on indirect comparison of Erigeron breviscapus injection and Breviscapus injection in treatment of acute ischemic stroke.
10.19540/j.cnki.cjcmm.20170121.026
- Author:
Yu-Fang ZHANG
1
;
Xi-Tong KE
1
;
Bao-Cai LI
1
;
Cheng XIANG
1
;
Song ZHAO
2
Author Information
1. Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, China.
2. Department of Geratology, the Second People's Hospital of Yunnan Province, Kunming 650021, China.
- Publication Type:Journal Article
- Keywords:
Breviscapus injection;
Erigeron breviscapus injection;
Meta-analysis;
indirect comparison;
ischemic stroke
- From:
China Journal of Chinese Materia Medica
2017;42(6):1194-1201
- CountryChina
- Language:Chinese
-
Abstract:
Erigeron breviscapus injection(DZXI) and Breviscapus injection(DZSI) are two popular injections in treatment of acute ischemic stroke in China. Both of them are manufactured from a same herbal medicine, E. breviscapus, but DZXI is an herbal extract(mixture) preparation and DZSI is a pure compound injection. This article was aimed to systemically evaluate and compare their efficacy and safety in treatment of acute ischemic stroke. The randomized controlled trials(RCTs) were collected for comparing DZXI and DZSI with Salvia miltiorrhiza injection(FDI) as the medium, and they were compared with indirect Meta-analysis(ITC). Thirty-nine RCTs with 4 180 patients were included. Meta-analysis results showed that both DZXI and DZSI had better efficacy than FDI in acute ischemic stroke. In the indirect comparison, DZSI had a higher total efficacy than DZXI, with significantly statistical differences[OR=0.634, 95%CI = (0.432,0.928), P<0.000 01], but there was no significant difference in improvement of neurological deficit [MD=-1.19, 95%CI=(－3.57,1.19), P=0.953]. On the safety aspect, adverse reaction rate of DZXI was 1.14%, mainly including head swelling, fever and chills while DZSI had no significant adverse reactions. The limited evidences in this study showed that Breviscapine injection had higher total efficiency and safety than E. breviscapine injection, but due to the low quality of the included RCTs, these two medicines should be comprehensively compared in further high-quality clinical trials.
